image credit: Adobe Stock

TherageniX to receive powdered gene therapy grant

September 5, 2023

The funding will boost the University of Nottingham spinout’s development of bone regeneration treatment

TherageniX, a company developing a dry powder gene therapy for bone graft augmentation, and the institution from which it emerged, the University of Nottingham, have been awarded a £995,000 grant from Innovate UK.

The funding will support the development of TherageniX’s powdered gene therapy, a non-viral gene delivery system to improve tissue regeneration after surgery. It will initially concentrate on orthopaedic applications, with the ultimate aim of improving outcomes for patients undergoing bone grafting procedures.

Read More on Pharma Times